Of the 290 patients, 47.2% (137/290) had TNBC, 31.3% (91/290) had HR+/HER2−, 6.9% (20/290) had HR+/HER2+, and 12.4% (36/290) had HR−/HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.